Abbott Laboratories delivered a stronger-than-expected second quarter and raised its full-year profit outlook. Revenue reached $12.59 billion, adjusted earnings were $1.31 per share, and the company increased its 2026 adjusted EPS forecast to $5.45-$5.60 from $5.38-$5.58.

$ABT rose around 12% as investors focused on resilient demand for cardiovascular devices, diabetes technology and cancer screening. Medical-device sales increased 9% to $5.85 billion, while diagnostics revenue reached $3.09 billion. The reported diagnostics increase included the Exact Sciences acquisition, while Cologuard generated mid-teens growth from new and repeat users.

Winners

Diversified medical-device companies

Names: $ABT (Abbott Laboratories), $BSX (Boston Scientific), $SYK (Stryker), $MDT (Medtronic)

Abbott is the direct win ...